Impact Of Whole-Body Fdg-Pet For The Detection Of Metastatic Tumors In Recurennt/Advanced Gynecological Malignancies

Current diagnostic techniques, including computed tomography (CT), magnetic resonance imaging (MRI) and ultrasonography (US) are not efficient for the detection of metastatic tumors in gynecological malignancies. Recently, whole-body positron emission tomography (PET) has been taken for patients with cancer. With the use of a labeled glucose analog (FDG), PET detects malignancy by depicting increased glucose uptake and metabolism in cancer cells. This study assessed the diagnostic accuracy of whole-body FDG-PET for the detection of tumor foci in 55 patients with suspected metastatic lesions of gynecological malignancies in comparison of CT, MRI and US, including specific tumor makers. We also evaluated if the availability of FDG-PET depended on the sites of recurrence. In this study, we concluded that FDG-PET had high sensitivity for detecting both intraperitoneal and retroperitoneal metastases (91% and 93%, respectively).